Maizinol™ for Sleep/Stress and UP360 for Immune Homeostasis

Unigen will introduce its two newest botanical ingredients for sleep/stress and immune health at this year’s SupplySide West Presentation Theater. Featured are Maizinol™, a natural alternative to melatonin, and UP360 for maintaining immune homeostasis. Both presentations are scheduled in the early afternoon of October 27th Supplier Presentation Theater and will be replayed online post-event on SSW 365 digital platform and www.unigen.net.

Maizinol™ is a patented ingredient derived from Zea mays corn leaf extract. Unigen’s Director of Pre-Clinical Development, Dr. Mesfin Yimam, DVM, MS, will present the detailed clinical results on Maizinol™, including mechanism of action, preclinical efficacy, and safety profile. In the double-blind placebo-controlled clinical trial of healthy subjects on sleep quality and overall wellbeing, a statistically significant and dose-correlated increase of approximately 30% deep sleep time, improvement of sleep quality, and reduction of salivary cortisol were observed. According to Dr. Qi Jia, Unigen CEO and CSO, “These collective health benefits give Maizinol™ a competitive edge in the market, to meet the needs from consumers who have experienced stress and lack of restful sleep under the rampage of the pandemic.” Another human clinical trial of Maizinol™ is in development with a larger cohort, per Dr. Jia. He added that Maizinol™ has a long history of safe human usage, once a-day dosing, lower cost per serving, and its high compatibility in formulating with other ingredients denotes its relative competitiveness to other similar ingredients on the market.

Dr. Jia will present significant pre-clinical and clinical data on Unigen’s immune health ingredient, UP360. The UP360 composition is comprised of polysaccharide and polyphenol standardized extracts from Aloe, Poria, and Rosemary that were formulated by evaluating the synergistic effects in protection of hyperoxia stressed macrophages. In an accelerated aging model, UP360 increased key innate and acquired immunity while protecting immune organs. Unigen also conducted a triple-blind placebo-controlled human clinical trial with influenza vaccine-immunized healthy subjects. UP360 resulted in a statistically significant increase of gamma delta T-cells, suggesting its benefits on enhanced immune surveillance in mucosal membranes.

For additional information on these newest Unigen ingredients, be sure to attend the Supplier Presentation Theater or stop by the Unigen Booth #2957. 2121 South State Street, Tacoma, WA 98405 | Main Tel: (253) 274-7160 | www.Unigen.net

About Unigen

Unigen discovers, develops, and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its ingredients through its high throughput screening PhytoLogix™ approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits. Mechanism of action, safety and efficacy are documented with extensive preclinical in vitro and in vivo testing and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacture, distribution, and marketing of end-products in each of Unigen’s target markets.
www.Unigen.net

MEDIA CONTACT:
Kathy Markham
Marketing Manager
Phone: 253.274.7165
Email: KMarkham@Unigen.net